Rein Therapeutics (NASDAQ:RNTX) Director Rickenbach Josef Von Purchases 23,190 Shares

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von acquired 23,190 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $1.06 per share, with a total value of $24,581.40. Following the acquisition, the director directly owned 58,014 shares of the company’s stock, valued at $61,494.84. This trade represents a 66.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Rein Therapeutics Trading Up 4.7%

Shares of RNTX traded up $0.05 during mid-day trading on Thursday, reaching $1.11. The stock had a trading volume of 425,172 shares, compared to its average volume of 1,491,003. Rein Therapeutics Inc. has a 52-week low of $0.95 and a 52-week high of $2.18. The business’s fifty day moving average is $1.33 and its 200 day moving average is $1.31.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. Sell-side analysts forecast that Rein Therapeutics Inc. will post -1.63 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Rein Therapeutics to a “sell” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Voss Capital LP boosted its stake in Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after buying an additional 1,577,437 shares during the period. Vanguard Group Inc. boosted its stake in Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after buying an additional 284,300 shares during the period. Prosight Management LP boosted its stake in Rein Therapeutics by 32.7% during the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock worth $650,000 after buying an additional 139,979 shares during the period. Cable Car Capital LP purchased a new position in Rein Therapeutics during the second quarter worth about $588,000. Finally, Sigma Planning Corp boosted its stake in Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after buying an additional 101,400 shares during the period. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.